[
  {
    "ts": null,
    "headline": "AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus",
    "summary": "Executives from AbbVie (NYSE:ABBV) outlined upcoming clinical milestones and development priorities across hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), and several earlier-stage immunology programs during a recent discussion focused on differentiation, combination strategies, and",
    "url": "https://finnhub.io/api/news?id=bd3c12c43910699b6200de73147f7652c971d6903d724fa7b9e250a0fb807ef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771243516,
      "headline": "AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus",
      "id": 139114149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Executives from AbbVie (NYSE:ABBV) outlined upcoming clinical milestones and development priorities across hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), and several earlier-stage immunology programs during a recent discussion focused on differentiation, combination strategies, and",
      "url": "https://finnhub.io/api/news?id=bd3c12c43910699b6200de73147f7652c971d6903d724fa7b9e250a0fb807ef1"
    }
  }
]